Managing Alzheimer’s and other neurodegenerative diseases is entering a new era, driven in part by the approval of two new Alzheimer’s drugs and the growing need for infrastructure capable of diagnosing dementia patients earlier and more efficiently and the recent U.S. FDA approval of brain specific PET scan technology.
While most investors have focused on pharmaceutical breakthroughs from major drug makers, Grey Matters Health Inc. (CSE: GREY) is taking a different path: building specialized neuroimaging clinics designed specifically for brain PET imaging in the field of nuclear medicine.
Formerly known as Algernon Health, the company recently rebranded to reflect its strategic focus on brain PET imaging and neurodegenerative disease diagnostics and is preparing for revenue in the next 2 quarters.
The timing could be important.
With the FDA approvals of new Alzheimer’s therapies such as Leqembi and Kisunla, demand for confirmatory brain imaging is expected to rise materially. These therapies require PET imaging or spinal tap confirmation before treatment is approved. The opportunity may be larger than many investors realize.
Grey Matters has moved away from focussing on developing drugs. Instead, the company is building what it believes could become critical diagnostic infrastructure through its planned NovaScan Neuroimaging Clinics network in the United States.
The company intends to deploy the FDA-cleared CareMiBrain PET Brain Imaging System, a compact, brain-optimized scanner designed specifically for neurological imaging.
Unlike traditional PET/CT systems, which are large, expensive, and primarily used for oncology and cardiac imaging, the CareMiBrain platform is significantly more compact, requires less infrastructure, and eliminates the CT (3D X-ray) component, reducing radiation exposure by approximately 25%, according to the company.
Grey Matters believes the current number of PET/CT U.S. imaging systems is not sufficient to handle the growing Alzheimer’s related diagnostic demand. Traditional PET/CT scanners are heavily utilized for abdominal cancer and cardiac imaging, creating potential capacity constraints for neurological applications.
Importantly, the opportunity extends beyond Alzheimer’s disease.
The company will also provide imaging services at its clinics for patients with Parkinson’s disease, lewy body dementia, epilepsy, multiple sclerosis, brain cancers, and other neurological indications as new isotope tracers enter the market. NovaScan also expects to be able to provide its brain PET scanners to contract research organizations involved in Phase 2 clinical trials for new advancing neurological drugs where the PET scanner is needed for disease confirmation.
The CareMiBrain PET system is materially different from conventional imaging infrastructure:
- Approximately 662 pounds versus up to 11,000 pounds for traditional PET/CT systems,
- Operates on standard wall power, while traditional PET/CT requires approximately US$250,000 in HVAC/electrical upgrade.
- Eliminates the CT component entirely and requires less infrastructure with 25% less radiation per patient
- Better patient experience sitting for brain scan as opposed to laying down and then being moved into a PET/CT machine which can cause dizziness and claustrophobic events
From a deployment perspective, that smaller scanner footprint could allow clinics to more easily operate in a wide variety of community-based outpatient settings rather than only large hospitals or large diagnosic centers.
For investors, Grey Matters represents a different kind of healthcare speculation story, one that is not focused on drug discovery, but on building the infrastructure supporting the next generation of neurodegenerative diagnostic and theragnostic needs.
Grey Matters estimates each clinic requires roughly US $1.1 million in capital investment, including scanner acquisition, shielding, equipment, furniture, and working capital.
The Alzheimer’s diagnostic landscape is rapidly evolving due to several converging trends, including U.S. FDA approvals of new Alzheimer’s therapies, expanding Medicare, Medicaid and private insurance reimbursement policies, an aging population, and the growing shift toward earlier disease detection. As more patients become eligible for treatment and monitoring, demand for specialized neuroimaging infrastructure could increase materially over the coming years.
The economics outlined in the company’s investor materials are notable:
- PET scans are billed at approximately US $4,500 per scan (covered by Medicare, Medicaid and private insurance).
- Net revenue per scan of roughly US $2,100 after isotope-related costs and rebates.
- Operational break-even at approximately 1.6 scans per day.
Grey Matters ultimately envisions a network of up to 200+ neuroimaging clinic locations across the United States.
Its first planned location in Davie, Florida, sits within a densely populated healthcare corridor serving approximately six million people within a one-hour drive radius, and is at the HCA Florida University Hospital Medical Offices.
The industry tailwind will also assist Grey Matters in executing its strategy. One of the most important catalyst when U.S. Medicare and Medicaid eliminated the previous lifetime limit of one amyloid PET scan per patient. That decision could materially expand repeat imaging demand as patients undergo treatment monitoring.
Building a national imaging network requires capital, operational expertise, physician referral pipelines, regulatory compliance, reimbursement execution, and patient acquisition capabilities.
However, the company is attempting to position itself within a segment of healthcare that may become increasingly important as Alzheimer’s diagnostics move toward earlier detection and larger patient volumes.
Rather than developing the drugs themselves, Grey Matters is effectively betting on the infrastructure surrounding the next generation of neurodegenerative disease management.
In healthcare investing, infrastructure providers can sometimes become just as important as the therapies driving demand.
The company also appears to have several favorable factors working in its favor, including improving testing regulations, aging population demographics, increasing demand for neurological imaging, and relationships with industry participants such as GE HealthCare Technologies, Catalyst MedTech, and other referral partners.
While the first few clinic locations will likely involve the steepest operational learning curve, successfully establishing workflows, reimbursement expertise, physician referral networks, and diagnostic protocols could create a meaningful operational advantage that makes future expansion significantly more scalable, efficient and potentially transform the business into a meaningful Cash-flow generating healthcare platform.
Beyond initial diagnosis, Alzheimer’s patients receiving monoclonal antibody therapies may require multiple follow-up PET scans to monitor treatment effectiveness, creating the potential for recurring imaging revenue and positioning Grey Matters and NovaScan more as a long-term healthcare services platform rather than simply an equipment deployment story.
However, the company appears to be positioning itself within a rapidly growing healthcare segment driven by earlier diagnosis, expanding treatment options, and increasing neurological healthcare needs, if management successfully executes its neuroimaging clinic strategy, the company could emerge as an early participant in a rapidly expanding neurological diagnostics market that remains largely underappreciated by the broader market today.
With a current market capitalization of approximately C$2.2 million, Grey Matters appears to be trading at a valuation that reflects very little of its long-term neuroimaging infrastructure ambitions, creating a potentially compelling asymmetrical speculative opportunity and meaning upside if the company can successfully commercialize and scale its clinic network model. For investors comfortable with early-stage healthcare and microcap volatility, Grey Matters Health may be a company worth adding to the watchlist.
Legal Disclaimer
General Information and Liability
This blog/article is curated by the content team of Ubika and SmallCapPower (“SCP”) and and is provided exclusively for informational purposes. No fees were received by Ubika and SmallCapPower for creation and distribution of the content. Ubika/SCP and their affiliates assume no responsibility for the accuracy, completeness, or timeliness of the information presented in this article. All content has been derived from publicly available, non‑material information deemed reliable but is not guaranteed by Ubika/SCP and its affiliates as to its accuracy or completeness.
Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or futures contracts in certain underlying companies mentioned in this site and in this article and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
No Endorsement or Financial Advice
Ubika Corp / SmallCapPower and it’s afiliates (“SCP”) does not own shares or have any financial interest in Grey Matters Health Inc. , however, shareholders of Ubika Corp / SmallCapPower and it’s afiliates (“SCP”) also own shares of Grey Matters Health Inc. Certain shareholders of Ubika Corp/SmallCapPower and their affiliates may also be affiliated with Grey Matters Health Inc. and may hold official positions in Grey Matters Health Inc. SCP’s role is strictly limited to managing and distributing this Article. SCP does not provide, endorse, or imply any form of financial, legal, or investment advice, nor does it recommend or endorse the purchase or sale of securities related to Grey Matters Health Inc. SCP has not been paid any fees for the distribution of this content.
Risk Disclaimer
Investing in securities, including those of Grey Matters Health Inc. , involves inherent risks, including the potential loss of capital. Neither SCP nor Grey Matters Health Inc. assumes responsibility for any direct, indirect, consequential, or incidental damages or losses incurred by individuals relying on the information provided in this newsletter.
Forward‑Looking Statements
This article/blog may contain forward‑looking statements as defined by Canadian and U.S. securities laws. Such statements reflect Grey Matters Health Inc. ’s current expectations and views of future events and may include terms such as “expects,” “anticipates,” “plans,” and “believes,” among others. These statements involve risks, uncertainties, and assumptions that may cause actual results to differ materially from those projected. Grey Matters Health Inc. does not undertake any obligation to update these forward‑looking statements except as required by law. Additional details can be found in Grey Matters Health Inc. ’s publicly available filings at www.sedar.com.
Due Diligence and Professional Advice
Readers are strongly encouraged to perform their own due diligence before making any investment decisions. This includes reviewing Grey Matters Health Inc. ’s publicly available financial statements, reports, and other filings, or consulting with independent financial or legal advisors for tailored advice.
No Offer or Solicitation
This article/blog does not constitute an offer to sell or a solicitation to buy any securities or financial instruments. Investment decisions made by individuals are their sole responsibility and should be based on their own judgment and analysis. This content is not a substitute for professional investment advice.
Limitation of Ubika Corp., SmallCapPower (SCP) and their Affiliates Role and Responsibilities
Ubika/SCP and their affiliates involvement is limited to distributing this article/blog. The content provided in this article is based on the publicly available sources and analysis performed by Ubika/SCP content team, which is based on several assumptions that may not be accurate. Ubika/SCP and their affiliates are not liable for errors, omissions, or inaccuracies in the content or any actions taken by readers based on this information.
Acknowledgement and Agreement
By engaging with this article/blog/site/email, you acknowledge that you have read, understood, and agreed to this legal disclaimer. You accept that reliance on the information provided is at your own risk.
